ArticleRheumatology and immunology research2025
Crystal deposition disease of the shoulder at uncommon sites: Diagnostic challenges and nomenclature issues in the absence of synovial fluid analysis.
Article in Rheumatology and immunology research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Calcium pyrophosphate deposition (CPPD) disease is a common, age-related crystalline arthropathy with diverse clinical presentations. While the knees and wrists are most frequently affected, shoulder involvement is increasingly recognized, occurring in up to 13% of cases, though often underdiagnosed. This mini-review provides a comprehensive overview of the epidemiology, pathogenesis, clinical manifestations, diagnosis, and treatment of shoulder CPPD, contextualized by an illustrative case of a 78-year-old woman with atypical calcifications in the axillary recess and supraspinatus muscle. A key focus is the diagnostic challenge when synovial fluid analysis, the gold standard for crystal confirmation, is technically unfeasible, a common scenario in clinical practice. We systematically discuss modern imaging techniques (ultrasound, dual-energy computed tomography [CT], conventional radiography) and demonstrate the practical application of the 2023 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) classification criteria for establishing probable CPPD when crystal analysis is unavailable. The review addresses critical differential diagnosis considerations, particularly distinguishing CPPD from basic calcium phosphate (BCP) deposition disease, and summarizes evidence-based therapeutic strategies for acute pseudogout flares and chronic inflammatory arthritis, including emerging biologic therapies targeting the interleukin-1 (IL-1) pathway. This comprehensive resource aids clinicians managing shoulder calcifications in the absence of definitive crystal confirmation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.